nContact’s Hybrid Convergent Procedure Takes Aim At Persistent AF

Executive Summary

Positive clinical results were presented at this year’s Boston AF Symposium on nContact Surgical Inc.’s minimally invasive Convergent Procedure, a combined epicardial and endocardial approach for treating patients with persistent atrial fibrillation, who currently have no good treatment options outside of open surgery. According to the company, about 50% of the entire AF population could potentially benefit from the Convergent Procedure, representing a potential patient market of nearly $15 billion.